Xencor (XNCR) EBITDA Margin (2013 - 2026)
Xencor (XNCR) posted quarterly EBITDA Margin of 1724.14% for Q1 2026, down 159221.0% year-over-year from N/an in Q1 2025, and down 807.82% quarter-over-quarter from 189.92% in Q4 2025.
Xencor (XNCR) EBITDA Margin (2013 - 2026) Analysis & Trends
Xencor (XNCR) has reported EBITDA Margin for 14 consecutive years, with 1724.14% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 159221.0% year-over-year to 1724.14%; the TTM figure through Mar 2026 stood at 217.93% (down 8673.0% YoY), while the FY2025 annual figure was 141.35%, up 2012.0% from the prior year.
- EBITDA Margin eased to 1724.14% in Q1 2026 per XNCR's latest filing, from 189.92% in the prior quarter.
- Across five years, EBITDA Margin topped out at 30.96% in Q1 2022 and bottomed at 1724.14% in Q1 2026.
- Historically, EBITDA Margin has averaged 242.2% across 5 years, with a median of 140.47% in 2022.
- Annual changes were most pronounced in 2025 — EBITDA Margin jumped 20978 bps — and 2026, when it tumbled 159221 bps.
- Xencor's EBITDA Margin stood at 197.1% in 2022, then jumped by 73 bps to 53.61% in 2023, then surged by 53 bps to 24.96% in 2024, then sank by 661 bps to 189.92% in 2025, then sank by 808 bps to 1724.14% in 2026.
- Business Quant data shows XNCR's EBITDA Margin at 1724.14% in Q1 2026, 189.92% in Q4 2025, and 226.29% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | -72.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -72.37% |
| Mar 31, 2026 | -1,724.14% |
| Dec 31, 2025 | -189.92% |
| Sep 30, 2025 | -226.29% |
| Jun 30, 2025 | -76.07% |
| Mar 31, 2025 | -131.93% |
| Dec 31, 2024 | -24.96% |
| Sep 30, 2024 | -310.17% |
| Jun 30, 2024 | -231.61% |
| Mar 31, 2024 | -341.71% |
| Dec 31, 2023 | -53.61% |
| Sep 30, 2023 | -30.86% |
| Jun 30, 2023 | -57.14% |
| Mar 31, 2023 | -319.71% |
| Dec 31, 2022 | -197.10% |
| Sep 30, 2022 | -140.47% |
| Jun 30, 2022 | -92.72% |
| Mar 31, 2022 | 30.96% |
| Dec 31, 2021 | 59.51% |
| Sep 30, 2021 | -209.83% |